In October 2007, the FDA announced which the labeling for all PDE5 inhibitors, together with tadalafil, needs a more outstanding warning from the likely risk of unexpected hearing decline as the results of post-advertising stories of short term deafness related to use of PDE5 inhibitors.[19]El tadalafilo puede causar efectos secundarios. Informe a